Atezolizumab Trial for Metastatic Cervical Carcinoma Completes Primary Phase

The Phase 3 trial (NCT03556839) investigating atezolizumab in combination with platinum chemotherapy, paclitaxel, and bevacizumab for metastatic carcinoma of the cervix reached its primary completion on 2025-08-31. This study enrolled 410 participants to evaluate the efficacy of this regimen.

Background

The trial focuses on patients with Stage IVB, persistent or recurrent carcinoma of the cervix. Atezolizumab is an anti programmed death-ligand 1 (anti-PD-L1) agent. This study explores the efficacy of combining atezolizumab with the current standard of care, which involves cisplatin or carboplatin/paclitaxel/bevacizumab. The integration of an anti-PD-L1 agent into this established regimen aims to improve outcomes for this patient population.

Trial design

The study (NCT03556839) is a randomized open-label Phase 3 trial that enrolled 410 participants. It investigates the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin/paclitaxel in patients with Stage IVB, persistent or recurrent carcinoma of the cervix. The trial design specifically explores the combination of bevacizumab plus atezolizumab, allowing for an all-comer assessment of atezolizumab activity without patient selection based on PD-L1 expression. This approach aims to provide a broad understanding of atezolizumab's potential in this setting when added to the existing standard of care.

What this means

The primary completion of this Phase 3 trial indicates that the main data collection period for the primary endpoint has concluded. Clinicians and researchers will await the full results to understand the potential impact of adding atezolizumab to the current standard of care for patients with metastatic carcinoma of the cervix.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT03556839, titled "Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix," was recorded as primary completion on 2025-08-31 on clinicaltrials.gov.